The acquisition underscores Olympus' plan to expand orthopedic minimally invasive surgery products, both organically and through mergers and acquisitions.
The company announced the U.S. commercial launch of the Matriform Si, a silicated synthetic bone graft substitute designed and cleared for spinal fusion.
Bioventus received FDA 510(k) clearance to market SIGNAFUSE® Bioactive Bone Graft in a strip format. The strips consist of 55% bioglass by weight and have been shown to induce higher levels of osteoblast differentiation compared to other synthetic bone graft strips....
Regenerative medicine is an emerging market with solutions to not only heal but also grow tissue and bone. Renovos is addressing the issue of biological molecule diffusion through a synthetic nanoclay gel technology platform called Renovite.
Biocomposites commenced U.S. launch of STIMULAN® Rapid Cure 3cc synthetic calcium sulfate, designed specifically for smaller voids in the foot and ankle.
Advanced Medical Solutions acquired Biomatlante, developer, and manufacturer of orthobiologic products with application in joint reconstruction, spine, trauma, and sports medicine procedures.
NuVasive's 3Q19 growth was driven by sales of U.S. spinal hardware as the company continues to evangelize adoption of minimally invasive spinal surgery.
Graftys completed a ‚¬4.1MM (~US $4.6MM) funding round. Proceeds will support commercialization of QuickSet cement and HBS injectable calcium phosphate bone graft substitute.
Innovasis entered into a private-label agreement with Stability Biologics that includes access to Physio® bone allograft. Product launch is expected by year-end.
The first patient has been treated in a multicenter study comparing Kuros Bioscience's MagnetOs bone graft substitute vs. autologous bone in spinal fusion.
Synergy Biomedical received FDA 510(k) clearance and commenced full launch of BIOSPHERE® MIS PUTTY for open, mini-open and percutaneous minimally invasive procedures.
Cerapedics received FDA approval for an IDE clinical trial of P-15L Peptide Enhanced Bone Graft vs. autograft in TLIF to treat degenerative disc disease.
Ortho Regenerative Technologies received an EU Notice of Allowance for a patent that will protect the composition of Ortho-R biopolymer for soft tissue repair.
Biomatlante's MBCP+ synthetic bone graft matrix has been selected for comparison to autograft in a 5-year trial in the treatment of long bone nonunions.
Premier is now offering Bioventus' full surgical orthobiologics product portfolio to its U.S. membership, comprising 3,750 hospitals and >130,000 provider organizations.
Amend Surgical entered into an exclusive agreement with The University of Florida Research Foundation to license patents for the development of Biomimetic Bone.
Interim results from study of BonyPid®-1000 bone substitute in the treatment of open tibial fractures indicate that the product met performance and safety endpoints in first patients at 6 months.
Studies of BonAlive® indicate that the naturally-antibacterial bioactive glass yields excellent results in the treatment of osteomyelitis, without the use of local antibiotics.
SIRAKOSS was granted two U.S. patents covering synthetic bone graft technologies, and seeks to raise £3.5MM to £5.0MM in support of U.S. and EU regulatory approvals.
Zimmer Biomet launched PrimaGen Advanced™ Allograft, an autograft substitute comprising cancellous bone + demineralized cortical bone fibers with verified osteoinductivity.
Study results demonstrated a high rate of clinical success from a combination of Biomatlante's MBCP+™ synthetic bone graft plus mesenchymal stem cells, particularly in the treatment of long bone non-union fractures.
curasan received FDA 510(k) clearance to market CERASORB Ortho FOAM synthetic bone material for the treatment of bone defects in the extremities and pelvis.
BONESUPPORT raised SEK 327MM (~US $37MM). Funds will support clinical data collection, product pipeline development and expansion of CERAMENT sales in existing and new markets.
RTI Surgical received regulatory clearance for nanOss® Bioactive bone void filler in Australia, as well as CE Mark for nanOss Bioactive Loaded and nanOss Bioactive 3D in Europe.
BONESUPPORT received FDA approval to launch an Investigational Device Exemption study of CERAMENT G bone graft substitute in the treament of open diaphyseal tibial fractures.
Bone Biologics signed an option agreement with UCLA for an opportunity to exclusively license the use of Nell-1 bone growth factor in the treatment of osteoporosis.
Pre-clinical study results demonstrated that BONESUPPORT's CERAMENT™, loaded with rhBMP-2 + zoledronic acid in very low doses, was able to quantitatively/qualitatively generate a high amount of mineralized bone volume.
NuVasive announced launch of new products such as AttraX® Putty Biotextured™ bone graft, the Reline® Modular system, next-gen MAS® TLIF 2 technology, etc.
BONESUPPORT expanded its 2014 injectable bone substitute registry to include 230 CERAMENT™ G procedures, as well as procedures involving the CERAMENT V formulation.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more